MannKind/$MNKD
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About MannKind
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
Ticker
$MNKD
Sector
Primary listing
Employees
405
Headquarters
Website
MannKind Metrics
BasicAdvanced
$1.7B
57.51
$0.10
0.81
-
Price and volume
Market cap
$1.7B
Beta
0.81
52-week high
$7.15
52-week low
$3.38
Average daily volume
4.5M
Financial strength
Current ratio
3.288
Quick ratio
2.556
Long term debt to equity
-397.28
Total debt to equity
-505.995
Interest coverage (TTM)
2.41%
Profitability
EBITDA (TTM)
84.716
Gross margin (TTM)
75.18%
Net profit margin (TTM)
9.32%
Operating margin (TTM)
24.32%
Effective tax rate (TTM)
5.04%
Revenue per employee (TTM)
$770,000
Management effectiveness
Return on assets (TTM)
9.95%
Return on equity (TTM)
-22.97%
Valuation
Price to earnings (TTM)
57.513
Price to revenue (TTM)
5.358
Price to book
-38.8
Price to tangible book (TTM)
-33.5
Price to free cash flow (TTM)
38.749
Free cash flow yield (TTM)
2.58%
Free cash flow per share (TTM)
0.145
Growth
Revenue change (TTM)
17.44%
Earnings per share change (TTM)
23.47%
3-year revenue growth (CAGR)
60.27%
3-year earnings per share growth (CAGR)
-36.59%
10-year earnings per share growth (CAGR)
-24.41%
What the Analysts think about MannKind
Analyst ratings (Buy, Hold, Sell) for MannKind stock.
Bulls say / Bears say
In a 26-week study presented at the American Diabetes Association meeting, Afrezza delivered similar blood sugar control to injected insulin among 230 children aged 4 to 17, with no reported adverse lung effects. This supports an expansion of its pediatric label and could open up a new source of revenue in the large pediatric diabetes market (Reuters).
MannKind has entered a non-dilutive financing deal of up to $500 million with Blackstone, giving the company substantial funds to advance key pipeline projects—including pediatric Afrezza sBLA, MNKD-101 Phase 3, and MNKD-201—and to broaden its commercial footprint, all without diluting current shareholders (Blackstone).
The finalized agreement to acquire scPharmaceuticals for up to $360 million brings the FDA-approved FUROSCIX™ on-body furosemide infuser into MannKind’s portfolio, enabling the company to tap into the over $10 billion U.S. edema market and diversify beyond inhaled insulin and pulmonary therapies (RTTNews).
Data summarised monthly by Lightyear AI. Last updated on 2 Nov 2025.
MannKind Financial Performance
Revenues and expenses
MannKind Earnings Performance
Company profitability
MannKind News
AllArticlesVideos
SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH
Business Wire2 months ago
SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH
Business Wire2 months ago
MannKind, Backed By Blackstone, Expands Cardiorenal Focus With $360 Million Deal
Benzinga3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for MannKind stock?
MannKind (MNKD) has a market cap of $1.7B as of November 10, 2025.
What is the P/E ratio for MannKind stock?
The price to earnings (P/E) ratio for MannKind (MNKD) stock is 57.51 as of November 10, 2025.
Does MannKind stock pay dividends?
No, MannKind (MNKD) stock does not pay dividends to its shareholders as of November 10, 2025.
When is the next MannKind dividend payment date?
MannKind (MNKD) stock does not pay dividends to its shareholders.
What is the beta indicator for MannKind?
MannKind (MNKD) has a beta rating of 0.81. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.